{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:17:11Z","timestamp":1789708631948,"version":"4.0.1"},"reference-count":581,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science, Technological Development, and Innovation of the Republic of Serbia","award":["451-03-66\/2024-03\/200017"],"award-info":[{"award-number":["451-03-66\/2024-03\/200017"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over the years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline the DLBCL tumor biology behind the actual and potential drug targets and address the challenges and drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody\u2013drug conjugates, chimeric antigen receptors, bispecific antibodies and T-cell engagers, and immune checkpoint inhibitors. Candidate drugs explored in ongoing clinical trials are coupled with diverse toxicity issues and refractoriness to drugs. According to the literature on DLBCL, the promise for new therapeutic targets lies in epigenetic alterations, B-cell receptor and NF-\u03baB pathways. Herein, we present putative targets hiding in lipid pathways, ferroptosis, and the gut microbiome that could be used in addition to immuno-chemotherapy to improve the general health status of DLBCL patients, thus increasing the chance of being cured. It may be time to devote more effort to exploring DLBCL metabolism to discover novel druggable targets. We also performed a bibliometric and knowledge-map analysis of the literature on DLBCL published from 2014\u20132023.<\/jats:p>","DOI":"10.3390\/ijms252111384","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:07:04Z","timestamp":1729674424000},"page":"11384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5220-4334","authenticated-orcid":false,"given":"Romana","family":"Masnikosa","sequence":"first","affiliation":[{"name":"Department of Physical Chemistry, Vinca Institute of Nuclear Sciences\u2014National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-7253","authenticated-orcid":false,"given":"Zorica","family":"Cvetkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Hospital Centre Zemun, Vukova 9, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-595X","authenticated-orcid":false,"given":"David","family":"Piri\u0107","sequence":"additional","affiliation":[{"name":"Department of Physical Chemistry, Vinca Institute of Nuclear Sciences\u2014National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large b-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chen, B., Mao, T., Qin, X., Zhang, W., Watanabe, N., and Li, J. (2022). Role of estrogen receptor signaling pathway-related genes in diffuse large B-cell lymphoma and identification of key targets via integrated bioinformatics analysis and experimental validation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1029998"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10428190601187703","article-title":"The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma\u2014A population-based study","volume":"48","author":"Hasselblom","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_5","first-page":"708","article-title":"The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: A meta-analysis","volume":"11","author":"Kaya","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_6","first-page":"381","article-title":"Malignant lymphoma: A clinico-pathologic survey of 618 cases","volume":"18","author":"Gall","year":"1942","journal-title":"Am. J. Pathol."},{"key":"ref_7","unstructured":"Rappaport, H. (1966). Tumors of the Hematopoietic System, Armed Forces Institute of Pathology."},{"key":"ref_8","first-page":"234","article-title":"The Rappaport classification of non-Hodgkin\u2019s lymphomas: A closer look using other proposed classifications","volume":"7","author":"Garvin","year":"1980","journal-title":"Semin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kurz, K.S., Ott, M., Kalmbach, S., Steinlein, S., Kalla, C., Horn, H., Ott, G., and Staiger, A.M. (2023). Large B-cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new concepts. Cancers, 15.","DOI":"10.3390\/cancers15082285"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","article-title":"A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas","volume":"37","author":"Falini","year":"2023","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Karube, K., Satou, A., and Kato, S. (2024). New classifications of B-cell neoplasms: A comparison of 5th WHO and International Consensus classifications. Int. J. Hematol.","DOI":"10.1007\/s12185-024-03781-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.anndiagpath.2018.09.014","article-title":"Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.14694\/EdBook_AM.2015.35.e449","article-title":"ABC, GCB, and double-hit diffuse large B-cell lymphoma: Does subtype make a difference in therapy selection?","volume":"35","author":"Nowakowski","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/jclinpath-2019-206199","article-title":"Clinical significance of \u2018double-hit\u2019 and \u2018double-expression\u2019 lymphomas","volume":"73","author":"Ma","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s44313-024-00006-w","article-title":"Adding MYC\/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level","volume":"59","author":"Warnnissorn","year":"2024","journal-title":"Blood Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","article-title":"Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Cerhan","year":"2014","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2022.07.006","article-title":"Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group","volume":"268\u2013269","author":"Yenamandra","year":"2022","journal-title":"Cancer Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41375-022-01804-w","article-title":"Molecular profiling of EBV associated diffuse large B-cell lymphoma","volume":"37","author":"Frontzek","year":"2023","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ross, A.M., Leahy, C.I., Neylon, F., Steigerova, J., Flodr, P., Navratilova, M., Urbankova, H., Vrzalikova, K., Mundo, L., and Lazzi, S. (2023). Epstein-Barr virus and the pathogenesis of diffuse large B-cell lymphoma. Life, 13.","DOI":"10.3390\/life13020521"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/10668969221074604","article-title":"Fibrin-associated EBV-positive large B-cell lymphoma incidentally found within a multinodular goiter","volume":"30","author":"Dargent","year":"2022","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bilajac, E., Mahmutovi\u0107, L., Lundstrom, K., Glamo\u010dlija, U., \u0160utkovi\u0107, J., Sezer, A., and Hromi\u0107-Jahjefendi\u0107, A. (2022). Viral agents as potential drivers of diffuse large B-cell lymphoma tumorigenesis. Viruses, 14.","DOI":"10.3390\/v14102105"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Huguet, M., Navarro, J.T., Molt\u00f3, J., Ribera, J.M., and Tapia, G. (2023). Diffuse large B-cell lymphoma in the HIV setting. Cancers, 15.","DOI":"10.3390\/cancers15123191"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gergely, L., Udvardy, M., and Illes, A. (2024). The possible role of pathogens and chronic immune stimulation in the development of diffuse large B-cell lymphoma. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030648"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dada, R. (2023). Redefining precision management of r\/r large B-cell lymphoma: Novel antibodies take on CART and BMT in the quest for future treatment strategies. Cells, 12.","DOI":"10.3390\/cells12141858"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: Population-level projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40001-024-01833-4","article-title":"Specific mortality in patients with diffuse large B-cell lymphoma: A retrospective analysis based on the surveillance, epidemiology, and end results database","volume":"29","author":"Xu","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: An operational approach for clinical trials","volume":"11","author":"Scarimbolo","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: A comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e7194","DOI":"10.1002\/cam4.7194","article-title":"Myc rearrangement redefines the stratification of high-risk multiple myeloma","volume":"13","author":"Jin","year":"2024","journal-title":"Cancer Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Turdo, A., Gaggianesi, M., D\u2019Accardo, C., Porcelli, G., Bella, S.D., Cricchio, D., Pillitteri, I., Porcasi, R., Lo Iacono, M., and Verona, F. (2023). EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1266265"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cho, S.F., Yeh, T.J., Wang, H.C., Du, J.S., Gau, Y.C., Lin, Y.Y., Chuang, T.M., Liu, Y.C., Hsiao, H.H., and Moi, S.H. (2024). Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphoma. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-56583-4"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107924","DOI":"10.1016\/j.pharmthera.2021.107924","article-title":"Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge","volume":"229","author":"Lavacchi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rosenberger, A., Crossland, R.E., Dressel, R., Kube, D., Wolff, D., Wulf, G., Bickeb\u00f6ller, H., Dickinson, A., and Holler, E. (2024). A genome-wide association study on hematopoietic stem cell transplantation reveals novel genomic loci associated with transplant outcomes. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1280876"},{"key":"ref_41","unstructured":"Chapman, J., and Zhang, Y. (2023). Histology, Hematopoiesis. StatPearls, StatPearls Publishing."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105002","DOI":"10.1016\/j.isci.2022.105002","article-title":"B-cell receptor repertoire sequencing: Deeper digging into the mechanisms and clinical aspects of immune-mediated diseases","volume":"25","author":"Zheng","year":"2022","journal-title":"iScience"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Chiu, M.L., Goulet, D.R., Teplyakov, A., and Gilliland, G.L. (2019). Antibody structure and function: The basis for engineering therapeutics. Antibodies, 8.","DOI":"10.3390\/antib8040055"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/imr.12670","article-title":"Assessing human B cell repertoire diversity and convergence","volume":"284","author":"Imkeller","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lucas, A.H. (2003). Immunoglobulin gene construction: Human. eLS.","DOI":"10.1038\/npg.els.0001172"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Stebegg, M., Kumar, S.D., Silva-Cayetano, A., Fonseca, V.R., Linterman, M.A., and Graca, L. (2018). Regulation of the germinal center response. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02469"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imr.12755","article-title":"Germinal center-derived lymphomas: The darkest side of humoral immunity","volume":"288","author":"Mlynarczyk","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Papa, I., and Vinuesa, C.G. (2018). Synaptic interactions in germinal centers. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01858"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.2020005857","article-title":"The dangers of d\u00e9j\u00e0 vu: Memory B cells as the cells of origin of ABC-DLBCLs","volume":"136","author":"Venturutti","year":"2020","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Shimkus, G., and Nonaka, T. (2023). Molecular classification and therapeutics in diffuse large B-cell lymphoma. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1124360"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nri2204","article-title":"BLIMP1 guides the fate of effector B and T cells","volume":"7","author":"Nutt","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-018-0130-3","article-title":"Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma","volume":"8","author":"Wenzl","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10238-022-00968-0","article-title":"The dynamic functions of IRF4 in B cell malignancies","volume":"23","author":"Maffei","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-\u03baB pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/leu.2015.57","article-title":"IL10 receptor is a novel therapeutic target in DLBCLs","volume":"29","author":"Sawh","year":"2015","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Naoi, Y., and Ennishi, D. (Int. J. Hematol., 2024). Understanding the intrinsic biology of diffuse large B-cell lymphoma: Recent advances and future prospects, Int. J. Hematol., online ahead of print.","DOI":"10.1007\/s12185-024-03780-6"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ng0993-66","article-title":"LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas","volume":"5","author":"Kerckaert","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1158\/1541-7786.MCR-22-0567","article-title":"B-cell lymphoma 6 (BCL6): From master regulator of humoral immunity to oncogenic driver in pediatric cancers","volume":"20","author":"McLachlan","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)00020-0","article-title":"BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control","volume":"13","author":"Shaffer","year":"2000","journal-title":"Immunity"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","article-title":"Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact","volume":"129","author":"Ennishi","year":"2017","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2015-08-662635","article-title":"The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling","volume":"127","author":"Flori","year":"2016","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12792","article-title":"Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment","volume":"291","author":"Young","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wasik, M.A., Kim, P.M., and Nejati, R. (2024). Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: Pathogenetic insights and translational implications. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1383741"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ghaderi, A., Daneshmanesh, A.H., Moshfegh, A., Kokhaei, P., V\u00e5gberg, J., Schultz, J., Olin, T., Harrysson, S., Smedby, K.E., and Drakos, E. (2020). ROR1 is expressed in diffuse large B-cell lymphoma (DLBCL) and a small molecule inhibitor of ROR1 (KAN0441571C) induced apoptosis of lymphoma cells. Biomedicines, 8.","DOI":"10.3390\/biomedicines8060170"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.5858\/2003-127-1148-CTIINL","article-title":"Chromosomal translocations involved in non-Hodgkin lymphomas","volume":"127","author":"Vega","year":"2003","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00018-023-05042-w","article-title":"Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma","volume":"81","author":"Gopalakrishnan","year":"2024","journal-title":"Cell. Mol. Life. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2320421121","DOI":"10.1073\/pnas.2320421121","article-title":"TRAF3 loss-of-function reveals the noncanonical NF-kappaB pathway as a therapeutic target in diffuse large B cell lymphoma","volume":"121","author":"Li","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e20230941","DOI":"10.1084\/jem.20230941","article-title":"Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL","volume":"221","author":"Eken","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.seminhematol.2023.11.006","article-title":"Biological heterogeneity in diffuse large B-cell lymphoma","volume":"60","author":"Hilton","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13353-023-00804-5","article-title":"Molecular complexity of diffuse large B-cell lymphoma: A molecular perspective and therapeutic implications","volume":"65","author":"Almasmoum","year":"2024","journal-title":"J. Appl. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma: Why so many types of subtypes?","volume":"196","author":"Morin","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Cao, B., Sun, C., Bi, R., Liu, Z., Jia, Y., Cui, W., Sun, M., Yu, B., Li, X., and Zhou, X. (2024). Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics. BMC Med. Genom., 17.","DOI":"10.1186\/s12920-024-01866-y"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1002\/ctm2.694","article-title":"Single-cell RNA sequencing technologies and applications: A brief overview","volume":"12","author":"Liang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Xu, H., Zhang, M., and Li, L. (2022). Single-cell RNA-seq and bulk RNA-seq reveal intratumoral heterogeneity and tumor microenvironment characteristics in diffuse large B-cell lymphoma. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.881345"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"110713","DOI":"10.1016\/j.celrep.2022.110713","article-title":"A single-cell atlas of diffuse large B cell lymphoma","volume":"39","author":"Ye","year":"2022","journal-title":"Cell Rep."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Carreras, J., Hiraiwa, S., Kikuti, Y.Y., Miyaoka, M., Tomita, S., Ikoma, H., Ito, A., Kondo, Y., Roncador, G., and Garcia, J.F. (2021). Artificial neural networks predicted the overall survival and molecular subtypes of diffuse large B-cell lymphoma using a pancancer immune-oncology panel. Cancers, 13.","DOI":"10.3390\/cancers13246384"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/make3030036","article-title":"Artificial neural network analysis of gene expression data predicted non-Hodgkin lymphoma subtypes with high accuracy","volume":"3","author":"Carreras","year":"2021","journal-title":"Mach. Learn. Knowl. Extr."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1038\/s41467-018-07232-8","article-title":"Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas","volume":"9","author":"Rosario","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Sinkala, M., Mulder, N., and Patrick Martin, D. (2019). Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers. Commun. Biol., 2.","DOI":"10.1038\/s42003-019-0666-1"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1610819","DOI":"10.3389\/pore.2023.1610819","article-title":"A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma","volume":"29","author":"Hou","year":"2023","journal-title":"Pathol. Oncol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"332","DOI":"10.37349\/etat.2024.00221","article-title":"Artificial intelligence and classification of mature lymphoid neoplasms","volume":"5","author":"Carreras","year":"2024","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_103","first-page":"37","article-title":"Artificial intelligence analysis of gene expression data predicted the prognosis of patients with diffuse large B-cell lymphoma","volume":"45","author":"Carreras","year":"2020","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/ai2010008","article-title":"Combination of multilayer perceptron, radial basis function artificial neural networks and machine learning image segmentation for the dimension reduction and the prognosis assessment of diffuse large B-cell lymphoma","volume":"2","author":"Carreras","year":"2021","journal-title":"AI"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3892\/ol.2024.14423","article-title":"Partial remission with sintilimab monotherapy in a patient carrying a CD274 amplification in refractory diffuse large B-cell lymphoma: A case report","volume":"27","author":"Zhang","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2017.251","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"32","author":"Karube","year":"2018","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/HS9.0000000000000023","article-title":"DLBCL Coast to Coast","volume":"2","author":"Tesio","year":"2018","journal-title":"HemaSphere"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41576-021-00348-6","article-title":"Origins of human disease: The chrono-epigenetic perspective","volume":"22","author":"Oh","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: From laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"a034959","DOI":"10.1101\/cshperspect.a034959","article-title":"Epigenetic mechanisms in leukemias and lymphomas","volume":"10","author":"Duy","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.seminhematol.2015.01.003","article-title":"The epigenetic basis of diffuse large B-cell lymphoma","volume":"52","author":"Jiang","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOH.0000000000000249","article-title":"The many layers of epigenetic dysfunction in B-cell lymphomas","volume":"23","author":"Jiang","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","article-title":"Germinal center B cell dynamics","volume":"45","author":"Mesin","year":"2016","journal-title":"Immunity"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Li, X., Ye, Y., Peng, K., Zeng, Z., Chen, L., and Zeng, Y. (2022). Histones: The critical players in innate immunity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1030610"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications\u2014Cause and consequence of genome function","volume":"23","author":"Burton","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1002\/mco2.292","article-title":"Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Wang, Z., Li, Y., Peng, H., Liu, J., Zhang, J., and Xiao, X. (2023). The role of CREBBP\/EP300 and its therapeutic implications in hematological malignancies. Cancer, 15.","DOI":"10.3390\/cancers15041219"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","article-title":"CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-018-0089-0","article-title":"Integrated DNA\/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay","volume":"8","author":"Intlekofer","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","article-title":"Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice","volume":"129","author":"Tadros","year":"2017","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"994","DOI":"10.7150\/ijms.8522","article-title":"Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance","volume":"11","author":"Lee","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Van, H.T., Xie, G., Dong, P., Liu, Z., and Ge, K. (2024). KMT2 Family of H3K4 methyltransferases: Enzymatic activity-dependent and -independent functions. J. Mol. Biol., 436.","DOI":"10.1016\/j.jmb.2024.168453"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Boss","year":"2015","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Wu, C., Song, Q., Gao, S., and Wu, S. (2024). Targeting HDACs for diffuse large B-cell lymphoma therapy. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-50956-x"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1038\/s41467-024-47012-1","article-title":"Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/cas.13655","article-title":"Oncogenic roles of enhancer of zeste homolog 1\/2 in hematological malignancies","volume":"109","author":"Nakagawa","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12185-016-2124-x","article-title":"Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies","volume":"105","author":"Sashida","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/1878-0261.12744","article-title":"The DNA methylation landscape of hematological malignancies: An update","volume":"14","author":"Blecua","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Chen, L., Ganz, P.A., and Sehl, M.E. (2022). DNA methylation, aging, and cancer risk: A mini-review. Front. Bioinform., 2.","DOI":"10.3389\/fbinf.2022.847629"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/j.1349-7006.2010.01569.x","article-title":"DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas","volume":"101","author":"Amara","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13238-020-00796-6","article-title":"The function and regulation of TET2 in innate immunity and inflammation","volume":"12","author":"Cong","year":"2021","journal-title":"Protein Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3324\/haematol.2013.088740","article-title":"Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma","volume":"98","author":"Asmar","year":"2013","journal-title":"Haematologica"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3960\/jslrt.56.145","article-title":"TET2 mutation in diffuse large B-cell lymphoma","volume":"56","author":"Kubuki","year":"2017","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/2159-8290.CD-18-0657","article-title":"TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis","volume":"8","author":"Dominguez","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2013-07-509885","article-title":"Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes","volume":"123","author":"Chambwe","year":"2014","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13148-024-01680-4","article-title":"Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length","volume":"16","author":"Carlund","year":"2024","journal-title":"Clin. Epigenet."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","article-title":"Non-coding RNAs in disease: From mechanisms to therapeutics","volume":"25","author":"Nemeth","year":"2024","journal-title":"Nat. Rev. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Dragomir, M.P., Manyam, G.C., Ott, L.F., Berland, L., Knutsen, E., Ivan, C., Lipovich, L., Broom, B.M., and Calin, G.A. (2020). FuncPEP: A database of functional peptides encoded by non-coding RNAs. Noncoding RNA, 6.","DOI":"10.3390\/ncrna6040041"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"148480","DOI":"10.1016\/j.gene.2024.148480","article-title":"Noncoding RNAs in B cell non-Hodgkins lymphoma","volume":"917","author":"Dini","year":"2024","journal-title":"Gene"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/or.2016.5236","article-title":"Non-coding RNAs as regulators in epigenetics (Review)","volume":"37","author":"Wei","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.2147\/JIR.S460730","article-title":"LncRNAs in immune and stromal cells remodel phenotype of cancer cell and tumor microenvironment","volume":"17","author":"Li","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Petri, A., Dybk\u00e6r, K., B\u00f8gsted, M., Thrue, C.A., Hagedorn, P.H., Schmitz, A., B\u00f8dker, J.S., Johnsen, H.E., and Kauppinen, S. (2015). Long noncoding RNA expression during human B-cell development. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138236"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13073-015-0230-7","article-title":"Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma","volume":"7","author":"Verma","year":"2015","journal-title":"Genome Med."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Wang, X., Lu, Y., Liu, Z., Zhang, Y., He, Y., Sun, C., Li, L., Zhai, Q., Meng, B., and Ren, X. (2022). A 9-lncRNA signature for predicting prognosis and immune response in diffuse large B-cell lymphoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.813031"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hon.3004","article-title":"LncRNA FIRRE stimulates PTBP1-induced Smurf2 decay, stabilizes B-cell receptor, and promotes the development of diffuse large B-cell lymphoma","volume":"40","author":"Liu","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"201112","DOI":"10.1016\/j.humgen.2022.201112","article-title":"Biomedical impact of the expression of HOX locus-associated LncRNAs HOTAIR and HOTTIP in diffuse large B cell lymphoma","volume":"34","author":"Habieb","year":"2022","journal-title":"Human Gene"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/jcmm.17795","article-title":"Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review","volume":"27","author":"Khanmohammadi","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","article-title":"MicroRNA: Trends in clinical trials of cancer diagnosis and therapy strategies","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Alsaadi, M., Khan, M.Y., Dalhat, M.H., Bahashwan, S., Khan, M.U., Albar, A., Almehdar, H., and Qadri, I. (2021). Dysregulation of miRNAs in DLBCL: Causative factor for pathogenesis, diagnosis and prognosis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11101739"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12935-024-03293-6","article-title":"MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: Targeting PD-1\/PD-L1 and CTLA-4 pathways","volume":"24","author":"Vahidi","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Larrabeiti-Etxebarria, A., Lopez-Santillan, M., Santos-Zorrozua, B., Lopez-Lopez, E., and Garcia-Orad, A. (2019). Systematic review of the potential of microRNAs in diffuse large B cell lymphoma. Cancers, 11.","DOI":"10.3390\/cancers11020144"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Yu, C.Y., and Kuo, H.C. (2019). The emerging roles and functions of circular RNAs and their generation. J. Biomed. Sci., 26.","DOI":"10.1186\/s12929-019-0523-z"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.canlet.2015.06.003","article-title":"Circular RNA: A new star of noncoding RNAs","volume":"365","author":"Qu","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41419-024-06698-3","article-title":"The role of circular RNAs in regulating resistance to cancer immunotherapy: Mechanisms and implications","volume":"15","author":"Ma","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/cas.15402","article-title":"CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a\/b to disinhibit PD-L1","volume":"113","author":"Dong","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.2019003764","article-title":"piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL","volume":"137","author":"Han","year":"2021","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtn.2021.04.021","article-title":"Epigenetics: Roles and therapeutic implications of non-coding RNA modifications in human cancers","volume":"25","author":"Rong","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41576-020-00295-8","article-title":"The epitranscriptome beyond m(6)A","volume":"22","author":"Wiener","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","article-title":"The role of m6A RNA methylation in cancer metabolism","volume":"21","author":"An","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12032-024-02402-9","article-title":"Role of m(6)A modifications in immune evasion and immunotherapy","volume":"41","author":"Wu","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Wang, T.L., Miao, X.J., Shuai, Y.R., Sun, H.P., Wang, X., Yang, M., and Zhang, N. (2024). FAT1 inhibits the proliferation of DLBCL cells via increasing the m(6)A modification of YAP1 mRNA. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-62793-7"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Emilius, L., Bremm, F., Binder, A.K., Schaft, N., and D\u00f6rrie, J. (2024). Tumor antigens beyond the human exome. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094673"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jgg.2020.04.006","article-title":"DNA methyltransferases in hematological malignancies","volume":"47","author":"Hoang","year":"2020","journal-title":"J. Genet. Genom."},{"key":"ref_172","first-page":"186","article-title":"Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax","volume":"109","author":"Zhu","year":"2024","journal-title":"Haematologica"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2020002580","article-title":"Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes","volume":"4","author":"Scholze","year":"2020","journal-title":"Blood Adv."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/cas.15040","article-title":"Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan","volume":"112","author":"Izutsu","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","article-title":"A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features","volume":"26","author":"Sarkozy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3892\/mmr.2021.11947","article-title":"Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs\/STAT3\/Bcl-2 pathway","volume":"23","author":"Zhang","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41419-019-2210-0","article-title":"Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20","volume":"11","author":"Guan","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13148-020-00948-9","article-title":"Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin. Epigenet."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hon.3088","article-title":"Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy","volume":"41","author":"Cao","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Singh, A., Rappolee, D.A., and Ruden, D.M. (2023). Epigenetic reprogramming in mice and humans: From fertilization to primordial germ cell development. Cells, 12.","DOI":"10.3390\/cells12141874"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41590-019-0427-9","article-title":"B cell signaling in context","volume":"20","author":"Kwak","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"ra93","DOI":"10.1126\/scisignal.2005887","article-title":"B cell antigen receptors of the IgM and IgD classes are clustered in different protein islands that are altered during B cell activation","volume":"8","author":"Maity","year":"2015","journal-title":"Sci. Signal."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41467-019-08677-1","article-title":"Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane","volume":"10","author":"Wildhagen","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: Preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","article-title":"Tonic B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"130","author":"Havranek","year":"2017","journal-title":"Blood"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton\u2019s tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"113329","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): Current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: Their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-91439-8_7","article-title":"Ibrutinib","volume":"212","author":"Charalambous","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12935-020-01518-y","article-title":"Ibrutinib in B-cell lymphoma: Single fighter might be enough?","volume":"20","author":"Xue","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Eng. J. Med."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Kozaki, R., Yasuhiro, T., Kato, H., Murai, J., Hotta, S., Ariza, Y., Sakai, S., Fujikawa, R., and Yoshida, T. (2023). Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton\u2019s tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0282166"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3324\/haematol.2021.278654","article-title":"Acalabrutinib for treatment of diffuse large B-cell lymphoma: Results from a phase Ib study","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Goodstal, S.M., Lin, J., Crandall, T., Crowley, L., Bender, A.T., Pereira, A., Soloviev, M., Wesolowski, J.S., Iadevaia, R., and Schelhorn, S.E. (2023). Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-47735-z"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-024-47198-4","article-title":"Combination of acalabrutinib with lenalidomide and rituximab in relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma: A single-arm phase II trial","volume":"15","author":"Park","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1182\/bloodadvances.2022009257","article-title":"BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5","volume":"7","author":"Oien","year":"2023","journal-title":"Blood Adv."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00432-024-05615-7","article-title":"Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K\/AKT\/mTOR pathway","volume":"150","author":"Wu","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Grondona, P., Bucher, P., Schulze-Osthoff, K., Hailfinger, S., and Schmitt, A. (2018). NF-\u03baB activation in lymphoid malignancies: Genetics, signaling, and targeted therapy. Biomedicines, 6.","DOI":"10.3390\/biomedicines6020038"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Staudt, L.M. (2010). Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol., 2.","DOI":"10.1101\/cshperspect.a000109"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.celrep.2015.03.059","article-title":"An oncogenic role for alternative NF-\u03baB signaling in DLBCL revealed upon deregulated BCL6 expression","volume":"11","author":"Zhang","year":"2015","journal-title":"Cell Rep."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/ejh.12792","article-title":"Rewired NF\u03baB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma","volume":"97","author":"Knittel","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation\u2014Lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: New insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.12846","article-title":"Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse\/primary refractory diffuse large B-cell lymphoma","volume":"166","author":"Feldman","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3026(17)30016-9","article-title":"Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: An open label, single-arm, multicentre phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Deeb","year":"2011","journal-title":"Cancer"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.13945","article-title":"Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 1b study from GELTAMO group","volume":"173","author":"Redondo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","article-title":"Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial","volume":"11","author":"Zinzani","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s13402-023-00833-6","article-title":"Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma","volume":"46","author":"Jin","year":"2023","journal-title":"Cell Oncol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1039\/D0RA08769F","article-title":"Characterizing the structure-activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase","volume":"11","author":"Tung","year":"2021","journal-title":"RSC Adv."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2131751","DOI":"10.1080\/09537104.2022.2131751","article-title":"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib","volume":"34","author":"Cooper","year":"2023","journal-title":"Platelets"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","article-title":"A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"54","author":"Flinn","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/j.clml.2018.05.022","article-title":"An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma","volume":"18","author":"Burke","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"57","DOI":"10.18632\/oncotarget.28352","article-title":"Spleen tyrosine kinase\/FMS-like tyrosine kinase-3 inhibition in relapsed\/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: Updated data with mivavotinib (TAK-659\/CB-659)","volume":"14","author":"Gordon","year":"2023","journal-title":"Oncotarget"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.critrevonc.2017.02.003","article-title":"Enzastaurin: A lesson in drug development","volume":"112","author":"Bourhill","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Kawano, T., Inokuchi, J., Eto, M., Murata, M., and Kang, J.H. (2021). Activators and inhibitors of protein kinase C (PKC): Their applications in clinical trials. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111748"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: Architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: From mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical Notch signaling pathway: Unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Arruga, F., Vaisitti, T., and Deaglio, S. (2018). The NOTCH pathway and its mutations in mature B cell malignancies. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00550"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.4049\/jimmunol.0903661","article-title":"Notch2 signaling is required for potent antitumor immunity in vivo","volume":"184","author":"Sugimoto","year":"2010","journal-title":"J. Immunol."},{"key":"ref_232","first-page":"837","article-title":"The role of oncogenic Notch2 signaling in cancer: A novel therapeutic target","volume":"9","author":"Xiu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/bloodadvances.2020002995","article-title":"Notch activation is pervasive in SMZL and uncommon in DLBCL: Implications for Notch signaling in B-cell tumors","volume":"5","author":"Shanmugam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.18632\/aging.205463","article-title":"Activation of Notch-1 signaling pathway in macrophages to secrete PD-L1 and regulate cytotoxicity of CAR-T cells in diffuse large B-cell lymphoma","volume":"16","author":"Li","year":"2024","journal-title":"Aging"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Griffioen, M.S., de Leeuw, D.C., Janssen, J.J.W.M., and Smit, L. (2022). Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies. Cancers, 14.","DOI":"10.3390\/cancers14143456"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: A review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/JCO.2024.42.16_suppl.7012","article-title":"Randomized phase II\/III study of R-CHOP +\/\u2212 venetoclax in previously untreated MYC\/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701","volume":"42","author":"Abramson","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1182\/bloodadvances.2023010964","article-title":"Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress","volume":"7","author":"Horn","year":"2023","journal-title":"Blood Adv."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Pierrat, O.A., Liu, M., Collie, G.W., Shetty, K., Rodrigues, M.J., Le Bihan, Y.V., Gunnell, E.A., McAndrew, P.C., Stubbs, M., and Rowlands, M.G. (2022). Discovering cell-active BCL6 inhibitors: Effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-23264-z"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2021.12.035","article-title":"An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo","volume":"529","author":"Xing","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/imr.12734","article-title":"MYC in germinal center-derived lymphomas: Mechanisms and therapeutic opportunities","volume":"288","author":"Bisso","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000505892","article-title":"The spectrum of MYC alterations in diffuse large B-cell lymphoma","volume":"143","author":"Xia","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1158\/1078-0432.CCR-15-2296","article-title":"Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma","volume":"22","author":"Deng","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"107631","DOI":"10.1016\/j.pharmthera.2020.107631","article-title":"Targeting BET bromodomain proteins in cancer: The example of lymphomas","volume":"215","author":"Spriano","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"586","DOI":"10.37349\/etat.2021.00065","article-title":"The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type","volume":"2","author":"Tarantelli","year":"2021","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1074\/jbc.R109.078105","article-title":"Chemical inducers of targeted protein degradation","volume":"285","author":"Raina","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acs.biochem.1c00464","article-title":"Ligandability of E3 ligases for targeted protein degradation applications","volume":"62","author":"Belcher","year":"2023","journal-title":"Biochemistry"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cpt.2985","article-title":"Clinical translation of targeted protein degraders","volume":"114","author":"Kong","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"215716","DOI":"10.1016\/j.canlet.2022.215716","article-title":"Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development","volume":"539","author":"Lv","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Rej, R.K., Allu, S.R., Roy, J., Acharyya, R.K., Kiran, I.N.C., Addepalli, Y., and Dhamodharan, V. (2024). Orally bioavailable proteolysis-targeting chimeras: An innovative approach in the golden era of discovering small-molecule cancer drugs. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040494"},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Shah Zaib Saleem, R., Schwalm, M.P., and Knapp, S. (2024). Expanding the ligand spaces for E3 ligases for the design of protein degraders. Bioorg. Med. Chem., 105.","DOI":"10.1016\/j.bmc.2024.117718"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/2472555221991104","article-title":"Small-molecule degraders beyond PROTACs-challenges and opportunities","volume":"26","author":"Kastl","year":"2021","journal-title":"SLAS Discov."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jb\/mvad113","article-title":"Protein degraders\u2014From thalidomide to new PROTACs","volume":"175","author":"Ito","year":"2024","journal-title":"J. Biochem."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic\u2014A new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141461","article-title":"Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-137750","article-title":"Ktx-120, a novel irakimid degrader of IRAK4 and IMiD substrates shows preferential activity and induces regressions in MYD88-mutant DLBCL CDX and PDX models","volume":"136","author":"Walker","year":"2020","journal-title":"Blood"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.2023022993","article-title":"Degraders upgraded: The rise of PROTACs in hematological malignancies","volume":"143","author":"Casan","year":"2024","journal-title":"Blood"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-024-01533-w","article-title":"Targeted protein degradation in hematologic malignancies: Latest updates from the 2023 ASH annual meeting","volume":"17","author":"Zhong","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First results from a phase 1, first-in-human study of the Bruton\u2019s tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood-2023-179508","article-title":"Initial findings from a first-in-human phase 1a\/b trial of NX-5948, a selective Bruton\u2019s tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Searle","year":"2023","journal-title":"Blood"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton\u2019s tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","article-title":"mTOR as a central hub of nutrient signalling and cell growth","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-024-06547-3","article-title":"mTOR pathway occupies a central role in the emergence of latent cancer cells","volume":"15","author":"Aleksandrova","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Karatrasoglou, E.A., Dimou, M., Piperidou, A., Lakiotaki, E., Korkolopoulou, P., and Vassilakopoulos, T.P. (2023). The role of mTOR in B cell lymphoid malignancies: Biologic and therapeutic aspects. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814110"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-065X.2010.00934.x","article-title":"Role of PI3K in the generation and survival of B cells","volume":"237","author":"Werner","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.neo.2018.03.002","article-title":"Clinical significance of PTEN deletion, mutation, and loss of PTEN expression in de novo diffuse large B-cell lymphoma","volume":"20","author":"Wang","year":"2018","journal-title":"Neoplasia"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","article-title":"Mutations of the PIK3CA gene in diffuse large B cell lymphoma","volume":"17","author":"Baohua","year":"2008","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","article-title":"mTOR inhibition amplifies the anti-lymphoma effect of PI3K\u03b2\/\u03b4 blockage in diffuse large B-cell lymphoma","volume":"37","author":"Xu","year":"2023","journal-title":"Leukemia"},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Masnikosa, R., Piri\u0107, D., Post, J.M., Cvetkovi\u0107, Z., Petrovi\u0107, S., Paunovi\u0107, M., Vu\u010di\u0107, V., and Bindila, L. (2023). Disturbed plasma lipidomic profiles in females with diffuse large B-cell lymphoma: A pilot study. Cancers, 15.","DOI":"10.3390\/cancers15143653"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41401-021-00644-1","article-title":"SAF-248, a novel PI3K\u03b4-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma","volume":"43","author":"Zhang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"20406207211006027","DOI":"10.1177\/20406207211006027","article-title":"Update on the role of copanlisib in hematologic malignancies","volume":"12","author":"Le","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Porpaczy, E., Wohlfarth, P., K\u00f6nigsbr\u00fcgge, O., Rabitsch, W., Skrabs, C., Staber, P., Worel, N., M\u00fcllauer, L., Simonitsch-Klupp, I., and Kornauth, C. (2021). Influence of TP53 mutation on survival of diffuse large B-cell lymphoma in the CAR T-cell era. Cancers, 13.","DOI":"10.3390\/cancers13225592"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/med.21637","article-title":"Targeting MDM2 for novel molecular therapy: Beyond oncology","volume":"40","author":"Wang","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1182\/blood-2019-129009","article-title":"Targeting MDM2 and XIAP by idasanutlin in diffuse large B-cell lymphoma","volume":"134","author":"Gu","year":"2019","journal-title":"Blood"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-136221","article-title":"Combination of idasanutlin, venetoclax and obinutuzumab in patients with relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL): Results from a phase I\/II study","volume":"136","author":"Kamdar","year":"2020","journal-title":"Blood"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/icb.2017.71","article-title":"IL4 and IL21 cooperate to induce the high Bcl6 protein level required for germinal center formation","volume":"95","author":"Chevrier","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2024.02.018","article-title":"Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers","volume":"57","author":"Shehata","year":"2024","journal-title":"Immunity"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12185-023-03692-x","article-title":"STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment","volume":"119","author":"Benoit","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"749","DOI":"10.18632\/oncotarget.28473","article-title":"CDK9 INHIBITORS: A promising combination partner in the treatment of hematological malignancies","volume":"14","author":"Morillo","year":"2023","journal-title":"Oncotarget"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-022-00875-6","article-title":"A new perspective on immune evasion: Escaping immune surveillance by inactivating tumor suppressors","volume":"7","author":"Mergener","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","article-title":"Cancer immune escape: The role of antigen presentation machinery","volume":"149","author":"Kallingal","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Priestley","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"e2104504118","DOI":"10.1073\/pnas.2104504118","article-title":"Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma","volume":"118","author":"Fangazio","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Takahara, T., Nakamura, S., Tsuzuki, T., and Satou, A. (2023). The immunology of DLBCL. Cancers, 15.","DOI":"10.3390\/cancers15030835"},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Trzos, S., Link-Lenczowski, P., and Poche\u0107, E. (2023). The role of N-glycosylation in B-cell biology and IgG activity. The aspects of autoimmunity and anti-inflammatory therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1188838"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s43018-022-00506-7","article-title":"Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy","volume":"4","author":"Lester","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_296","unstructured":"Goodman, S.R. (2021). Regulated Cell Death. Goodman\u2019s Medical Cell Biology, Academic Press. [4th ed.]."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","article-title":"A guide to cell death pathways","volume":"25","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","article-title":"Regulated cell death (RCD) in cancer: Key pathways and targeted therapies","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"e30831","DOI":"10.1016\/j.heliyon.2024.e30831","article-title":"Analyzing the involvement of diverse cell death-related genes in diffuse large B-cell lymphoma using bioinformatics techniques","volume":"10","author":"Feng","year":"2024","journal-title":"Heliyon"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"eabd5016","DOI":"10.1126\/scitranslmed.abd5016","article-title":"ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy","volume":"13","author":"Ianniciello","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41375-024-02147-4","article-title":"Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach","volume":"38","author":"Mandhair","year":"2024","journal-title":"Leukemia"},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Hsu, C.M., Chang, K.C., Chuang, T.M., Chu, M.L., Lin, P.W., Liu, H.S., Kao, S.Y., Liu, Y.C., Huang, C.T., and Wang, M.H. (2023). High G9a expression in DLBCL and its inhibition by niclosamide to induce autophagy as a therapeutic approach. Cancers, 15.","DOI":"10.3390\/cancers15164150"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: Beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell Signal."},{"key":"ref_304","doi-asserted-by":"crossref","unstructured":"Poulard, C., Noureddine, L.M., Pruvost, L., and Le Romancer, M. (2021). Structure, activity, and function of the protein lysine methyltransferase G9a. Life, 11.","DOI":"10.3390\/life11101082"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","article-title":"Glutathione synthesis","volume":"1830","author":"Lu","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12964-023-01267-1","article-title":"Iron and copper: Critical executioners of ferroptosis, cuproptosis and other forms of cell death","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"e24857","DOI":"10.1016\/j.heliyon.2024.e24857","article-title":"GPX4 is a potential diagnostic and therapeutic biomarker associated with diffuse large B lymphoma cell proliferation and B cell immune infiltration","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cbpa.2017.11.003","article-title":"Protein lipoylation: An evolutionarily conserved metabolic regulator of health and disease","volume":"42","author":"Rowland","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10495-024-01983-0","article-title":"Mechanisms of cuproptosis and its relevance to distinct diseases","volume":"29","author":"Lou","year":"2024","journal-title":"Apoptosis"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12943-023-01732-y","article-title":"Cuproptosis: Mechanisms and links with cancers","volume":"22","author":"Xie","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_312","doi-asserted-by":"crossref","unstructured":"Zhang, B., Zhang, T., Zheng, Z., Lin, Z., Wang, Q., Zheng, D., Chen, Z., and Ma, Y. (2022). Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1020566"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Bai, X., Lu, F., Li, S., Zhao, Z., Wang, N., Zhao, Y., Ma, G., Zhang, F., Su, X., and Wang, D. (2024). Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-63433-w"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"ref_316","doi-asserted-by":"crossref","unstructured":"Piccolo, M., Ferraro, M.G., Iazzetti, F., Santamaria, R., and Irace, C. (2024). Insight into iron, oxidative stress and ferroptosis: Therapy targets for approaching anticancer strategies. Cancers, 16.","DOI":"10.3390\/cancers16061220"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.bbagen.2019.06.010","article-title":"Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases","volume":"1863","author":"Nakamura","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_318","doi-asserted-by":"crossref","unstructured":"Mortensen, M.S., Ruiz, J., and Watts, J.L. (2023). Polyunsaturated fatty acids drive lipid peroxidation during ferroptosis. Cells, 12.","DOI":"10.3390\/cells12050804"},{"key":"ref_319","doi-asserted-by":"crossref","unstructured":"Chen, X., Comish, P.B., Tang, D., and Kang, R. (2021). Characteristics and biomarkers of ferroptosis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.637162"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: Molecular mechanisms and health implications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jare.2018.03.005","article-title":"Synopsis of arachidonic acid metabolism: A review","volume":"11","author":"Hanna","year":"2018","journal-title":"J. Adv. Res."},{"key":"ref_322","doi-asserted-by":"crossref","unstructured":"Bian, W., Li, H., Chen, Y., Yu, Y., Lei, G., Yang, X., Li, S., Chen, X., Li, H., and Yang, J. (2024). Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL. Biomed. Pharmacother., 173.","DOI":"10.1016\/j.biopha.2024.116386"},{"key":"ref_323","first-page":"609","article-title":"Ferroptosis-related gene signature: A new method for personalized risk assessment in patients with diffuse large B-cell lymphoma","volume":"14","author":"Chen","year":"2021","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/CBM-230325","article-title":"Identification of a prognostic signature based on five ferroptosis-related genes for diffuse large B-cell lymphoma","volume":"40","author":"Li","year":"2024","journal-title":"Cancer Biomark."},{"key":"ref_325","doi-asserted-by":"crossref","unstructured":"Lee, J., and Roh, J.L. (2023). Unleashing ferroptosis in human cancers: Targeting ferroptosis suppressor protein 1 for overcoming therapy resistance. Antioxidants, 12.","DOI":"10.3390\/antiox12061218"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2016.12.009","article-title":"Contribution of the HNE-immunohistochemistry to modern pathological concepts of major human diseases","volume":"111","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"102027","DOI":"10.1016\/j.labinv.2024.102027","article-title":"Mediation of ferroptosis suppressor protein 1 expression via 4-hydroxy-2-nonenal accumulation contributes to acquisition of resistance to apoptosis and ferroptosis in diffuse large B-cell lymphoma","volume":"104","author":"Kawade","year":"2024","journal-title":"Lab. Investig."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2020009404","article-title":"Dimethyl fumarate induces ferroptosis and impairs NF-kappaB\/STAT3 signaling in DLBCL","volume":"138","author":"Schmitt","year":"2021","journal-title":"Blood"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.2022019274","article-title":"BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis","volume":"142","author":"Schmitt","year":"2023","journal-title":"Blood"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.2023021310","article-title":"Targeting epigenetics and ferroptosis in DLBCL","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"ref_331","doi-asserted-by":"crossref","unstructured":"Mynott, R.L., Habib, A., Best, O.G., and Wallington-Gates, C.T. (2023). Ferroptosis in haematological malignancies and associated therapeutic nanotechnologies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087661"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","article-title":"Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12943-024-01999-9","article-title":"Ferroptotic therapy in cancer: Benefits, side effects, and risks","volume":"23","author":"Diao","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s42255-023-00930-8","article-title":"Mitophagy in human health, ageing and disease","volume":"5","author":"Picca","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s00277-024-05635-w","article-title":"Leukemia and mitophagy: A novel perspective for understanding oncogenesis and resistance","volume":"103","author":"Liu","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_336","doi-asserted-by":"crossref","unstructured":"Ucche, S., and Hayakawa, Y. (2024). Immunological aspects of cancer cell metabolism. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105288"},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: Looking forward","volume":"21","author":"Chandel","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_338","doi-asserted-by":"crossref","unstructured":"Zhou, D., Duan, Z., Li, Z., Ge, F., Wei, R., and Kong, L. (2022). The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1091779"},{"key":"ref_339","doi-asserted-by":"crossref","unstructured":"Bhalla, K., Jaber, S., Nahid, M.N., Underwood, K., Beheshti, A., Landon, A., Bhandary, B., Bastian, P., Evens, A.M., and Haley, J. (2018). Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-19182-8"},{"key":"ref_340","doi-asserted-by":"crossref","unstructured":"Dai, L., Fan, G., Xie, T., Li, L., Tang, L., Chen, H., Shi, Y., and Han, X. (2024). Single-cell and spatial transcriptomics reveal a high glycolysis B cell and tumor-associated macrophages cluster correlated with poor prognosis and exhausted immune microenvironment in diffuse large B-cell lymphoma. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00605-w"},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41416-022-01848-w","article-title":"Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma","volume":"127","author":"Noble","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13046-024-02994-0","article-title":"A glutamine tug-of-war between cancer and immune cells: Recent advances in unraveling the ongoing battle","volume":"43","author":"Wang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells","volume":"5","author":"Vasseur","year":"2016","journal-title":"Oncogenesis"},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41389-022-00420-8","article-title":"Lipids in cancer: A global view of the contribution of lipid pathways to metastatic formation and treatment resistance","volume":"11","author":"Vasseur","year":"2022","journal-title":"Oncogenesis"},{"key":"ref_347","doi-asserted-by":"crossref","unstructured":"Zhang, L., Chang, N., Liu, J., Liu, Z., Wu, Y., Sui, L., and Chen, W. (2022). Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.987499"},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1042\/EBC20200067","article-title":"Mammalian lipids: Structure, synthesis and function","volume":"65","author":"Cockcroft","year":"2021","journal-title":"Essays Biochem."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_350","doi-asserted-by":"crossref","unstructured":"Fhu, C.W., and Ali, A. (2020). Fatty acid synthase: An emerging target in cancer. Molecules, 25.","DOI":"10.3390\/molecules25173935"},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"11818","DOI":"10.1073\/pnas.1205995109","article-title":"Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma","volume":"109","author":"Bhatt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/1535-7163.MCT-09-1061","article-title":"Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma","volume":"9","author":"Uddin","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ebiom.2018.01.014","article-title":"Metabolomic profiling reveals cellular reprogramming of B-cell lymphoma by a lysine deacetylase inhibitor through the choline pathway","volume":"28","author":"Pera","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood.V120.21.2711.2711","article-title":"Fatty acid metabolism in diffuse large B-cell lymphoma (DLBCL): Interaction with oncogenic cell signaling pathways and the identification of a novel treatment paradigm","volume":"120","author":"Dashnamoorthy","year":"2012","journal-title":"Blood"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.V126.23.1284.1284","article-title":"Lipid addiction of diffuse large B-cell lymphoma (DLBCL): Fatty acid synthase (FASN) and PI3K dependent cell death identifies a novel therapeutic paradigm","volume":"126","author":"Dashnamoorthy","year":"2015","journal-title":"Blood"},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1080\/10428194.2020.1742899","article-title":"Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma","volume":"61","author":"Gifford","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1038\/s41467-022-33138-7","article-title":"Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37","volume":"13","author":"Peeters","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_358","doi-asserted-by":"crossref","unstructured":"Enciu, A.M., Radu, E., Popescu, I.D., Hinescu, M.E., and Ceafalan, L.C. (2018). Targeting CD36 as biomarker for metastasis prognostic: How far from translation into clinical practice?. Biomed. Res. Int., 2018.","DOI":"10.1155\/2018\/7801202"},{"key":"ref_359","first-page":"4301","article-title":"Overexpression of CD36, driven by STAT3, mediates free fatty acid uptake in CLL cells","volume":"130","author":"Rozovski","year":"2017","journal-title":"Blood"},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12308-012-0166-4","article-title":"FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma","volume":"6","author":"Danilova","year":"2013","journal-title":"J. Hematop."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/0008-5472.CAN-22-0917","article-title":"Metabolic reprogramming in hematologic malignancies: Advances and clinical perspectives","volume":"82","author":"Yu","year":"2022","journal-title":"Cancer Res."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1080\/10428194.2021.2020782","article-title":"Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma","volume":"63","author":"Gouni","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"100295","DOI":"10.1016\/j.medntd.2024.100295","article-title":"Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma","volume":"22","author":"Liu","year":"2024","journal-title":"Med. Nov. Technol. Devices"},{"key":"ref_364","doi-asserted-by":"crossref","unstructured":"Rink, J.S., Lin, A.Y., McMahon, K.M., Calvert, A.E., Yang, S., Taxter, T., Moreira, J., Chadburn, A., Behdad, A., and Karmali, R. (2021). Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. J. Biol. Chem., 296.","DOI":"10.1074\/jbc.RA120.014888"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"e01857-20","DOI":"10.1128\/JVI.01857-20","article-title":"Epstein-Barr virus-encoded latent membrane protein 1 and B-cell growth transformation induce lipogenesis through fatty acid synthase","volume":"95","author":"Hulse","year":"2021","journal-title":"J. Virol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00277-010-0904-6","article-title":"Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma","volume":"89","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2017.01.004","article-title":"Plasma phospholipid changes are associated with response to chemotherapy in non-Hodgkin lymphoma patients","volume":"54","author":"Masnikosa","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_368","doi-asserted-by":"crossref","unstructured":"Fan, L., Lin, Q., Huang, X., Fu, D., and Huang, H. (2021). Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: A retrospective analysis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08963-6"},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"14198","DOI":"10.1021\/acs.analchem.8b02910","article-title":"Specific lipid and metabolic profiles of R-CHOP-resistant diffuse large B-cell lymphoma elucidated by matrix-assisted laser desorption ionization mass spectrometry imaging and in vivo imaging","volume":"90","author":"Claes","year":"2018","journal-title":"Anal. Chem."},{"key":"ref_370","doi-asserted-by":"crossref","unstructured":"Xu, Y., Shen, H., Shi, Y., Zhao, Y., Zhen, X., Sun, J., Li, X., Zhou, D., Yang, C., and Wang, J. (2023). Dyslipidemia in diffuse large B-cell lymphoma based on the genetic subtypes: A single-center study of 259 Chinese patients. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1172623"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1038\/s41467-023-42532-8","article-title":"Genome-wide association analysis of plasma lipidome identifies 495 genetic associations","volume":"14","author":"Ottensmann","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_372","doi-asserted-by":"crossref","unstructured":"Lehtim\u00e4ki, M., Mishra, B.H., Del-Val, C., Lyytik\u00e4inen, L.P., K\u00e4h\u00f6nen, M., Cloninger, C.R., Raitakari, O.T., Laaksonen, R., Zwir, I., and Lehtim\u00e4ki, T. (2023). Uncovering the complex genetic architecture of human plasma lipidome using machine learning methods. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-30168-z"},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1038\/s41467-019-11954-8","article-title":"Genetic architecture of human plasma lipidome and its link to cardiovascular disease","volume":"10","author":"Tabassum","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/ijc.31590","article-title":"Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma","volume":"143","author":"Gao","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_375","doi-asserted-by":"crossref","unstructured":"Huang, X., Wang, Y., Huang, Z., Chen, X., Lin, Q., Huang, H., and Fan, L. (2024). Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: A retrospective study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11818-5"},{"key":"ref_376","doi-asserted-by":"crossref","unstructured":"Beyene, H.B., Olshansky, G., Smith, A.A.T., Giles, C., Huynh, K., Cinel, M., Mellett, N.A., Cadby, G., Hung, J., and Hui, J. (2020). High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3001049"},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molmet.2018.05.008","article-title":"Sex differences in lipid and lipoprotein metabolism","volume":"15","author":"Palmisano","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12944-021-01456-2","article-title":"Age and sex are associated with the plasma lipidome: Findings from the GOLDN study","volume":"20","author":"Slade","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1126\/science.ade2879","article-title":"Loyal gut microbes","volume":"377","author":"Moeller","year":"2022","journal-title":"Science"},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cgh.2018.09.017","article-title":"Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians","volume":"17","author":"Allaband","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41579-023-00998-9","article-title":"Utilization of the microbiome in personalized medicine","volume":"22","author":"Ratiner","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_382","doi-asserted-by":"crossref","unstructured":"Al-Khazaleh, A.K., Chang, D., M\u00fcnch, G.W., and Bhuyan, D.J. (2024). The gut connection: Exploring the possibility of implementing gut microbial metabolites in lymphoma treatment. Cancers, 16.","DOI":"10.20944\/preprints202403.0892.v2"},{"key":"ref_383","doi-asserted-by":"crossref","unstructured":"Yuan, L., Wang, W., Zhang, W., Zhang, Y., Wei, C., Li, J., and Zhou, D. (2021). Gut microbiota in untreated diffuse large B cell lymphoma Patients. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.646361"},{"key":"ref_384","doi-asserted-by":"crossref","unstructured":"Koliada, A., Moseiko, V., Romanenko, M., Lushchak, O., Kryzhanovska, N., Guryanov, V., and Vaiserman, A. (2021). Sex differences in the phylum-level human gut microbiota composition. BMC Microbiol., 21.","DOI":"10.1186\/s12866-021-02198-y"},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2020.1848158","article-title":"Gut Bacteroides species in health and disease","volume":"13","author":"Zafar","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_386","first-page":"e19047","article-title":"The role of microbiota in the development of cancer tumour cells and lymphoma of B and T cells","volume":"13","author":"Mamgain","year":"2021","journal-title":"Cureus"},{"key":"ref_387","doi-asserted-by":"crossref","unstructured":"Riley, D.R., Sieber, K.B., Robinson, K.M., White, J.R., Ganesan, A., Nourbakhsh, S., and Dunning Hotopp, J.C. (2013). Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples. PLoS Comput. Biol., 9.","DOI":"10.1371\/journal.pcbi.1003107"},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"eaar7785","DOI":"10.1126\/science.aar7785","article-title":"The human gut bacterial genotoxin colibactin alkylates DNA","volume":"363","author":"Wilson","year":"2019","journal-title":"Science"},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1182\/bloodadvances.2020003129","article-title":"Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma","volume":"5","author":"Diefenbach","year":"2021","journal-title":"Blood Adv."},{"key":"ref_390","doi-asserted-by":"crossref","unstructured":"Lin, Z., Mao, D., Jin, C., Wang, J., Lai, Y., Zhang, Y., Zhou, M., Ge, Q., Zhang, P., and Sun, Y. (2023). The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1105293"},{"key":"ref_391","doi-asserted-by":"crossref","unstructured":"Akimova, E., Gassner, F.J., Greil, R., Zaborsky, N., and Geisberger, R. (2022). Detecting bacterial-human lateral gene transfer in chronic lymphocytic leukemia. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031094"},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.1208344","article-title":"Linking long-term dietary patterns with gut microbial enterotypes","volume":"334","author":"Wu","year":"2011","journal-title":"Science"},{"key":"ref_393","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zhang, Z., Xu, L., and Zhang, X. (2021). Maintaining the balance of intestinal flora through the diet: Effective prevention of illness. Foods, 10.","DOI":"10.3390\/foods10102312"},{"key":"ref_394","first-page":"2224","article-title":"The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma","volume":"141","author":"Yoon","year":"2023","journal-title":"Blood"},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood.2023019858","article-title":"Light shed from the gut in large B-cell lymphoma","volume":"141","author":"Bigenwald","year":"2023","journal-title":"Blood"},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/hematolrep16010007","article-title":"The gut microbiome correlated to chemotherapy efficacy in diffuse large B-cell lymphoma patients","volume":"16","author":"Xu","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_397","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Han, S., Xiao, X., Zheng, L., Chen, Y., Zhang, Z., Gao, X., Zhou, S., Yu, K., and Huang, L. (2023). Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1146861"},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1182\/bloodadvances.2023012246","article-title":"Dissecting causal links between gut microbiota, inflammatory cytokines, and DLBCL: A Mendelian randomization study","volume":"8","author":"Jiang","year":"2024","journal-title":"Blood Adv."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat. Med."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","article-title":"A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","volume":"29","author":"Saini","year":"2023","journal-title":"Nat. Med."},{"key":"ref_401","doi-asserted-by":"crossref","unstructured":"Zhang, P.F., and Xie, D. (2024). Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: A new hope?. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1362133"},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"key":"ref_403","doi-asserted-by":"crossref","unstructured":"Montoya, S., Soong, D., Nguyen, N., Affer, M., Munamarty, S.P., and Taylor, J. (2021). Targeted therapies in cancer: To be or not to be, selective. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111591"},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.4049\/jimmunol.1502033","article-title":"CD nomenclature 2015: Human leukocyte differentiation antigen workshops as a driving force in immunology","volume":"195","author":"Engel","year":"2015","journal-title":"J. Immunol."},{"key":"ref_405","doi-asserted-by":"crossref","unstructured":"Rastogi, I., Jeon, D., Moseman, J.E., Muralidhar, A., Potluri, H.K., and McNeel, D.G. (2022). Role of B cells as antigen presenting cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.954936"},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol. Investig."},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: A biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hon.3013","article-title":"Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper","volume":"40","author":"Bailly","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"20406207211027458","DOI":"10.1177\/20406207211027458","article-title":"The use of tafasitamab in diffuse large B-cell lymphoma","volume":"12","author":"Topp","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"2309701","DOI":"10.1080\/21645515.2024.2309701","article-title":"Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma","volume":"20","author":"Pirosa","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","article-title":"Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Salles","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_412","doi-asserted-by":"crossref","unstructured":"Pierpont, T.M., Limper, C.B., and Richards, K.L. (2018). Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00163"},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00011-022-01622-x","article-title":"CD20(+) T cells: An emerging T cell subset in human pathology","volume":"71","author":"Lee","year":"2022","journal-title":"Inflamm. Res."},{"key":"ref_414","doi-asserted-by":"crossref","unstructured":"Dabkowska, A., Domka, K., and Firczuk, M. (2024). Advancements in cancer immunotherapies targeting CD20: From pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1363102"},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: An \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2008.001024","article-title":"CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure","volume":"94","author":"Johnson","year":"2009","journal-title":"Haematologica"},{"key":"ref_417","doi-asserted-by":"crossref","unstructured":"Clark, E.A., and Giltiay, N.V. (2018). CD22: A regulator of innate and adaptive B cell responses and autoimmunity. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02235"},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40164-023-00454-7","article-title":"Targeting CD22 for B-cell hematologic malignancies","volume":"12","author":"Xu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S288546","article-title":"Targeting CD22 for the treatment of B-cell malignancies","volume":"10","author":"Shah","year":"2021","journal-title":"Immunotargets Ther."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: Phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-022-00644-2","article-title":"Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication","volume":"12","author":"Huo","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_423","doi-asserted-by":"crossref","unstructured":"Bobrowicz, M., Kubacz, M., Slusarczyk, A., and Winiarska, M. (2020). CD37 in B cell derived tumors-more than just a docking point for monoclonal antibodies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249531"},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood-2016-11-748137","article-title":"Staining the target: CD37 expression in lymphomas","volume":"128","author":"Bertoni","year":"2016","journal-title":"Blood"},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2174\/1871520616666160902100506","article-title":"Therapeutic use of brentuximab vedotin in CD30+ hematologic malignancies","volume":"17","author":"Fabbri","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: The new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"e1118","DOI":"10.1002\/ctm2.1118","article-title":"The dual role of CD70 in B-cell lymphomagenesis","volume":"12","author":"Nie","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41423-020-0490-z","article-title":"CD5 and B lymphocyte responses: Multifaceted effects through multitudes of pathways and channels","volume":"17","author":"Taher","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41590-023-01721-9","article-title":"Memory B cell subsets have divergent developmental origins that are coupled to distinct imprinted epigenetic states","volume":"25","author":"Callahan","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41590-024-01858-1","article-title":"IL-12 induces a B cell-intrinsic IL-12\/IFN\u03b3 feed-forward loop promoting extrafollicular B cell responses","volume":"25","author":"Elsner","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41577-024-00991-0","article-title":"New insights into the ontogeny, diversity, maturation and survival of long-lived plasma cells","volume":"24","author":"Fooksman","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_432","doi-asserted-by":"crossref","unstructured":"Lam, N., Lee, Y., and Farber, D.L. (Nat. Rev. Immunol, 2024). A guide to adaptive immune memory, Nat. Rev. Immunol, advance online publication.","DOI":"10.1038\/s41577-024-01040-6"},{"key":"ref_433","doi-asserted-by":"crossref","unstructured":"Kumar, M., Thangavel, C., Becker, R.C., and Sadayappan, S. (2020). Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity. Cancers, 13.","DOI":"10.3390\/cancers13010086"},{"key":"ref_434","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/mab.2021.0044","article-title":"Epitope mapping of rituximab using HisMAP method","volume":"41","author":"Asano","year":"2022","journal-title":"Monoclon. Antibodies Immunodiagn. Immunother."},{"key":"ref_437","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1021\/acs.analchem.1c00960","article-title":"Determination of the rituximab binding site to the CD20 epitope using SPOT synthesis and surface plasmon resonance analyses","volume":"93","author":"Bar","year":"2021","journal-title":"Anal. Chem."},{"key":"ref_438","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/19420862.2016.1255520","article-title":"Rethinking the INN system for therapeutic antibodies","volume":"9","author":"Pottier","year":"2017","journal-title":"MAbs"},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: Obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_440","doi-asserted-by":"crossref","unstructured":"Baah, S., Laws, M., and Rahman, K.M. (2021). Antibody-drug conjugates-A tutorial review. Molecules, 26.","DOI":"10.3390\/molecules26102943"},{"key":"ref_441","doi-asserted-by":"crossref","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_442","doi-asserted-by":"crossref","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"ref_443","doi-asserted-by":"crossref","unstructured":"Riccardi, F., Dal Bo, M., Macor, P., and Toffoli, G. (2023). A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1274088"},{"key":"ref_444","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_446","doi-asserted-by":"crossref","unstructured":"Sheyi, R., de la Torre, B.G., and Albericio, F. (2022). Linkers: An assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020396"},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_448","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_451","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1111\/bph.14784","article-title":"Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin","volume":"176","author":"Li","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_452","doi-asserted-by":"crossref","unstructured":"Al Sbihi, A., Alasfour, M., and Pongas, G. (2024). Innovations in antibody-drug conjugate (ADC) in the treatment of lymphoma. Cancers, 16.","DOI":"10.3390\/cancers16040827"},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.abo3923","article-title":"Cryo-EM structure of the human IgM B cell receptor","volume":"377","author":"Su","year":"2022","journal-title":"Science"},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.18341","article-title":"The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma","volume":"199","author":"Kawasaki","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207221087511","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: A review of clinical data","volume":"13","author":"Furqan","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: Opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_458","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-23765-3_1","article-title":"Current development of monoclonal antibodies in cancer therapy","volume":"214","author":"Parakh","year":"2020","journal-title":"Recent Results Cancer Res."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","article-title":"Advances in antibody-based therapy in oncology","volume":"4","author":"Zinn","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13543776.2018.1428307","article-title":"Therapeutic bispecific antibody formats: A patent applications review (1994\u20132017)","volume":"28","author":"Godar","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_464","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: Dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","article-title":"Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_466","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2018.08.010","article-title":"Building blocks for bispecific and trispecific antibodies","volume":"154","author":"Wu","year":"2019","journal-title":"Methods"},{"key":"ref_467","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: Trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Compte","year":"2023","journal-title":"Theranostics"},{"key":"ref_468","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and tri-specific antibodies in non-Hodgkin lymphoma: Current data and perspectives","volume":"14","author":"Dulery","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_469","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_470","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_471","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: First approval","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs"},{"key":"ref_472","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2022-169219","article-title":"Salvage treatment with novel agents is preferable to standard chemotherapy in patients with large B-cell lymphoma progressing after chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood"},{"key":"ref_473","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_474","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/17474086.2019.1676717","article-title":"Blinatumomab: A novel therapy for the treatment of non-Hodgkin\u2019s lymphoma","volume":"12","author":"Bukhari","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_475","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1097\/MJT.0000000000001009","article-title":"Blinatumomab-associated neurological adverse events","volume":"27","author":"Ahmed","year":"2020","journal-title":"Am. J. Ther."},{"key":"ref_476","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"ref_477","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_478","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 sudy: Odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"key":"ref_479","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A Phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma: Recommended dose safety\/efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_480","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: First approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_481","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: Safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"ref_482","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","article-title":"Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes","volume":"155","author":"Grimm","year":"1982","journal-title":"J. Exp. Med."},{"key":"ref_483","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"ref_484","doi-asserted-by":"crossref","unstructured":"Shafer, P., Kelly, L.M., and Hoyos, V. (2022). Cancer therapy with TCR-engineered T cells: Current strategies, challenges, and prospects. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.835762"},{"key":"ref_485","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"ref_486","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","article-title":"Enhanced cellular therapy: Revolutionizing adoptive cellular therapy","volume":"13","author":"Xu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_487","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1182\/blood-2022-158171","article-title":"Autologous stem cell transplant in 2nd line DLBCL in 2022, still the standard of care? A monocentric experience","volume":"140","author":"Collignon","year":"2022","journal-title":"Blood"},{"key":"ref_488","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41409-023-02156-4","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma","volume":"59","author":"Kato","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_489","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-024-00473-y","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in R\/R DLBCL patients with failure of CAR-T therapy","volume":"13","author":"Cong","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_490","doi-asserted-by":"crossref","unstructured":"Mehta, P.H., Fiorenza, S., Koldej, R.M., Jaworowski, A., Ritchie, D.S., and Quinn, K.M. (2021). T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.780442"},{"key":"ref_491","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_492","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_493","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_494","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41375-023-01976-z","article-title":"Who wins the combat, CAR or TCR?","volume":"37","author":"Yun","year":"2023","journal-title":"Leukemia"},{"key":"ref_495","doi-asserted-by":"crossref","unstructured":"Jayaraman, J., Mellody, M.P., Hou, A.J., Desai, R.P., Fung, A.W., Pham, A.H.T., Chen, Y.Y., and Zhao, W. (2020). CAR-T design: Elements and their synergistic function. EBioMedicine, 58.","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"ref_496","doi-asserted-by":"crossref","unstructured":"Tomasik, J., Jasi\u0144ski, M., and Basak, G.W. (2022). Next generations of CAR-T cells\u2014New therapeutic opportunities in hematology?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1034707"},{"key":"ref_497","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_498","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_499","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_500","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_501","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"key":"ref_502","doi-asserted-by":"crossref","unstructured":"Massaro, F., Andreozzi, F., Abrassart, T., Castiaux, J., Massa, H., Rizzo, O., and Vercruyssen, M. (2024). Beyond chemotherapy: Present and future perspectives in the treatment of lymphoproliferative disorders. Biomedicines, 12.","DOI":"10.3390\/biomedicines12050977"},{"key":"ref_503","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_504","doi-asserted-by":"crossref","unstructured":"Minnar, C.M., Lui, G., Gulley, J.L., Schlom, J., and Gameiro, S.R. (2023). Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1321318"},{"key":"ref_505","doi-asserted-by":"crossref","first-page":"109041","DOI":"10.1016\/j.intimp.2022.109041","article-title":"CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges","volume":"110","author":"Yousefi","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_506","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological malignancies: Recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_507","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: Combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_508","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.path.2019.03.012","article-title":"Prognostic and predictive biomarkers in diffuse large B-cell lymphoma","volume":"12","author":"Chan","year":"2019","journal-title":"Surg. Pathol. Clin."},{"key":"ref_509","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jnci\/djab194","article-title":"Epigenetic profiling and response to CD19 chimeric antigen receptor T-cell therapy in B-cell malignancies","volume":"114","author":"Villanueva","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_510","doi-asserted-by":"crossref","unstructured":"Nydegger, A., Novak, U., Kronig, M.N., Legros, M., Zeerleder, S., Banz, Y., Bacher, U., and Pabst, T. (2021). Transformed lymphoma is associated with a favorable response to CAR-T-cell treatment in DLBCL patients. Cancers, 13.","DOI":"10.3390\/cancers13236073"},{"key":"ref_511","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.seminhematol.2023.11.007","article-title":"CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?","volume":"60","author":"Kinoshita","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_512","doi-asserted-by":"crossref","unstructured":"Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., and Zhou, J. (2019). Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01237"},{"key":"ref_513","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s11684-022-0972-8","article-title":"Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy","volume":"17","author":"Yan","year":"2023","journal-title":"Front. Med."},{"key":"ref_514","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_515","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2023.41.16_suppl.2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"Locke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_516","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_517","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: A phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"ref_518","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, J., Wang, Z., Liu, Y., Wang, T., Zhang, M., Xia, C., Zhang, F., Huang, D., and Zhang, L. (2024). Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity. Cell Prolif., e13683.","DOI":"10.1111\/cpr.13683"},{"key":"ref_519","doi-asserted-by":"crossref","unstructured":"Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., and Li, Y. (2022). A bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.840956"},{"key":"ref_520","doi-asserted-by":"crossref","first-page":"2371664","DOI":"10.1080\/21645515.2024.2371664","article-title":"A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023","volume":"20","author":"Huang","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_521","doi-asserted-by":"crossref","first-page":"2291900","DOI":"10.1080\/21645515.2023.2291900","article-title":"A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023","volume":"19","author":"Li","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_522","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_523","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint inhibitors Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_524","doi-asserted-by":"crossref","unstructured":"Condoluci, A., and Rossi, D. (2022). Biology and treatment of Richter transformation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.829983"},{"key":"ref_525","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): A characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_526","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"key":"ref_527","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"ref_528","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1007\/s00277-023-05259-6","article-title":"Clinical significance of plasma PD-L1(+) exosomes in the management of diffuse large B cell lymphoma","volume":"102","author":"Xu","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_529","doi-asserted-by":"crossref","unstructured":"Modi, D., Potugari, B., and Uberti, J. (2021). Immunotherapy for diffuse large B-cell lymphoma: Current landscape and future directions. Cancers, 13.","DOI":"10.3390\/cancers13225827"},{"key":"ref_530","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_531","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: Potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_532","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.25659","article-title":"Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma","volume":"95","author":"Herrera","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_533","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hon.93_2629","article-title":"Safety and efficacy of the PD-L1 inhibitor Durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL","volume":"37","author":"Nowakowski","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_534","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hon.203_2631","article-title":"Safety and clinical activity of Atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large B-cell lymphoma: Primary analysis of a phase 1B study","volume":"37","author":"Palomba","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_535","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2019-123368","article-title":"Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): Updated analysis of a phase I\/II study","volume":"134","author":"Younes","year":"2019","journal-title":"Blood"},{"key":"ref_536","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","article-title":"Development of pharmacological immunoregulatory anti-cancer therapeutics: Current mechanistic studies and clinical opportunities","volume":"9","author":"Yin","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_537","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12967-024-05002-3","article-title":"Diffuse large B-cell lymphoma: The significance of CD8(+) tumor-infiltrating lymphocytes exhaustion mediated by TIM3\/Galectin-9 pathway","volume":"22","author":"Zhu","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_538","first-page":"100268","article-title":"CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies","volume":"16","author":"Sun","year":"2021","journal-title":"Leuk. Res. Rep."},{"key":"ref_539","doi-asserted-by":"crossref","unstructured":"Yang, H., Xun, Y., and You, H. (2023). The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark. Res., 11.","DOI":"10.1186\/s40364-023-00456-x"},{"key":"ref_540","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_541","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_542","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_543","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"ref_544","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.4103\/jfmpc.jfmpc_2432_21","article-title":"Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment","volume":"11","author":"Mamgain","year":"2022","journal-title":"J. Family Med. Prim. Care"},{"key":"ref_545","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management","volume":"96","author":"Barta","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_546","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-3-319-13150-4_11","article-title":"Management of diffuse large B-cell lymphoma (DLBCL)","volume":"165","author":"Kubuschok","year":"2015","journal-title":"Cancer Treat. Res."},{"key":"ref_547","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"key":"ref_548","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: Results of Intergroup National Clinical Trials Network Study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_549","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): A randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"ref_550","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_551","doi-asserted-by":"crossref","first-page":"101140","DOI":"10.1016\/j.blre.2023.101140","article-title":"A paradox of choice: Sequencing therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"63","author":"Brooks","year":"2024","journal-title":"Blood Rev."},{"key":"ref_552","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40487-024-00265-8","article-title":"Epidemiology and real-world treatment of incident diffuse large B-cell lymphoma (DLBCL): A German claims data analysis","volume":"12","author":"Pacis","year":"2024","journal-title":"Oncol. Ther."},{"key":"ref_553","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","article-title":"The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"12","author":"Lu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_554","first-page":"CD013365","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_555","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_556","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fon-2022-0774","article-title":"Lisocabtagene maraleucel in the treatment of relapsed\/refractory large B-cell lymphoma","volume":"19","author":"Gordon","year":"2023","journal-title":"Future Oncol."},{"key":"ref_557","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_558","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"ref_559","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.18335","article-title":"Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis","volume":"198","author":"Shargian","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_560","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: A paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"ref_561","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2023.283162","article-title":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: Patient-reported outcomes from the PILOT study","volume":"109","author":"Gordon","year":"2024","journal-title":"Haematologica"},{"key":"ref_562","doi-asserted-by":"crossref","first-page":"12052","DOI":"10.1182\/blood-2022-170669","article-title":"CAR-T cell therapy in first line for high risk diffuse large B-cell lymphoma: Review of efficacy and cost-effectiveness against standard of care chemo-immunotherapy","volume":"140","author":"Akbar","year":"2022","journal-title":"Blood"},{"key":"ref_563","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11912-023-01466-6","article-title":"Evolving role of CAR T cell therapy in first- and second-line treatment of large B cell lymphoma","volume":"25","author":"Lionel","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_564","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_565","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"ref_566","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-020-01405-w","article-title":"Tafasitamab: First approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_567","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_568","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: Real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"key":"ref_569","first-page":"320","article-title":"Lenalidomide in DLBCL: Are we past the cell of origin?","volume":"19","author":"Goldfinger","year":"2021","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_570","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2021-147765","article-title":"Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3)","volume":"138","author":"Luigi","year":"2021","journal-title":"Blood"},{"key":"ref_571","doi-asserted-by":"crossref","first-page":"TPS7574","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7574","article-title":"Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5","volume":"39","author":"Hamadani","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_572","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/13543784.2020.1800638","article-title":"Polatuzumab vedotin: An investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma","volume":"29","author":"Bourbon","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_573","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood.2023022048","article-title":"Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: No ordinary subgroup analysis","volume":"142","author":"Cliff","year":"2023","journal-title":"Blood"},{"key":"ref_574","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14712598.2024.2312243","article-title":"An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas","volume":"24","author":"Polgarova","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_575","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1060028019892643","article-title":"Selinexor: A first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma","volume":"54","author":"Peterson","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_576","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/or.2022.8325","article-title":"Bendamustine: A review of pharmacology, clinical use and immunological effects (Review)","volume":"47","author":"Aurer","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_577","doi-asserted-by":"crossref","unstructured":"Stokes, J., Molina, M.S., Hoffman, E.A., Simpson, R.J., and Katsanis, E. (2021). Immunomodulatory effects of bendamustine in hematopoietic cell transplantation. Cancers, 13.","DOI":"10.3390\/cancers13071702"},{"key":"ref_578","unstructured":"(2024, October 07). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_579","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez, C., Garrote-de-Barros, A., L\u00f3pez-Portugu\u00e9s, C., Hern\u00e1ndez-S\u00e1nchez, M., and D\u00edez, P. (2024). Characterization of human B cell hematological malignancies using protein-based approaches. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094644"},{"key":"ref_580","doi-asserted-by":"crossref","unstructured":"van der Meeren, L.E., Kluiver, J., Rutgers, B., Alsagoor, Y., Kluin, P.M., van den Berg, A., and Visser, L. (2019). A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223260"},{"key":"ref_581","doi-asserted-by":"crossref","unstructured":"Yanguas-Casas, N., Pedrosa, L., Fern\u00e1ndez-Miranda, I., and S\u00e1nchez-Beato, M. (2021). An overview on diffuse large B-cell lymphoma models: Towards a functional genomics approach. Cancers, 13.","DOI":"10.3390\/cancers13122893"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:18:28Z","timestamp":1760113108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":581,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ijms252111384"],"URL":"https:\/\/doi.org\/10.3390\/ijms252111384","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}